Literature DB >> 19232333

The effects of splicing variant of PXR PAR-2 on CYP3A4 and MDR1 mRNA expressions.

Yan Liu1, Wei Ji, You Yin, Lan Fan, Jian Zhang, Huang Yun, Nianci Wang, Qing Li, Zhang Wei, Dongshen Ouyang, Hong-Hao Zhou.   

Abstract

BACKGROUND: PAR-2(SV1), a splicing variant of PXR, has similar activity as PXR wild type. Currently, a 6bp-deletion variant ((-133)GAGAAG(-128)) in promoter region of PAR-2(SV1) was reported, which could diminish the hPAR-2 promote activity in HepG2 cells. The distribution and functions of 6bp-deletion in Chinese were investigated.
METHODS: The PXR genotype was analyzed from 56 liver samples and 177 blood samples. Then the mRNA expression of PAR-2(SV1), total PXR, CYP3A4 and MDR1 were quantitatively analyzed by real-time PCR.
RESULTS: The allelic frequencies of 6bp-deletion were 22.4%, 38.4% and 23.7%, in blood of Chinese healthy (n=177), hepatic carcinoma samples (n=33) and calculus of bile duct ones (n=23) respectively. PAR-2(SV1) transcript represented approximately 15.3% of the total PXR transcripts in all liver samples. The 6bp-deletion cut down PAR-2(SV1) mRNA and total PXR mRNA transcriptional expression, and then led to down regulations of MDR1 and CYP3A4.
CONCLUSIONS: PAR-2(SV1) plays an important role in total PXR mRNA expression. The 6bp-deletion affects the PAR-2(SV1) expression greatly, and then contributes to the adjustment of expression and function of total PXR. Thus it leads to the changed target gene expressions, which may partly explain interindividual variations in CYP3A4 and MDR1. And these phenomena suggest that individuals with 6bp-deletion are prone to carcinoma when exposed to toxicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19232333     DOI: 10.1016/j.cca.2009.02.006

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

Review 1.  Molecular mechanisms underlying chemical liver injury.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Expert Rev Mol Med       Date:  2012-02-03       Impact factor: 5.600

Review 2.  PXR-mediated idiosyncratic drug-induced liver injury: mechanistic insights and targeting approaches.

Authors:  Jingheng Wang; Monicah Bwayi; Rebecca R Florke Gee; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-06-16       Impact factor: 4.481

Review 3.  PXR variants: the impact on drug metabolism and therapeutic responses.

Authors:  C Trent Brewer; Taosheng Chen
Journal:  Acta Pharm Sin B       Date:  2016-07-27       Impact factor: 11.413

4.  CYP and SXR gene polymorphisms influence in opposite ways acute rejection rate in pediatric patients with renal transplant.

Authors:  Stefano Turolo; Alberto Edefonti; Luciana Ghio; Sara Testa; William Morello; Giovanni Montini
Journal:  BMC Pediatr       Date:  2020-05-25       Impact factor: 2.125

5.  Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer.

Authors:  Jihui Chen; Zhipeng Wang; Shouhong Gao; Kejin Wu; Fang Bai; Qiqiang Zhang; Hongyu Wang; Qin Ye; Fengjing Xu; Hong Sun; Yunshu Lu; Yan Liu
Journal:  Cancer Cell Int       Date:  2021-02-25       Impact factor: 6.429

Review 6.  Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation.

Authors:  Meng Yu; Mouze Liu; Wei Zhang; Yingzi Ming
Journal:  Curr Drug Metab       Date:  2018       Impact factor: 3.731

Review 7.  Regulation of CAR and PXR Expression in Health and Disease.

Authors:  Martine Daujat-Chavanieu; Sabine Gerbal-Chaloin
Journal:  Cells       Date:  2020-10-31       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.